Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors. (1st January 2017)

• Record Type: Journal Article
• Authors: Mollica, Adriano; Pelliccia, Sveva; Famiglini, Valeria; Stefanucci, Azzurra; Macedonio, Giorgia; Chiavaroli, Annalisa; Orlando, Giustino; Brunetti, Luigi; Ferrante, Claudio; Pieretti, Stefano; Novellino, Ettore; Benyhe, Sandor; Zador, Ferenc; Erdei, Anna; Szucs, Edina; Samavati, Reza; Dvrorasko, Szalbolch; Tomboly, Csaba; Ragno, Rino; Patsilinakos, Alexandros; Silvestri, Romano
• Is Part Of: Journal of enzyme inhibition and medicinal chemistry. Volume 32:Number 1(2017)
• Page Start: 444
• Page End: 451
• Publication Date: 2017-01-01
• Subjects: Cannabinoid receptor CB1R -- Rimonabant -- opioids -- bivalent ligand -- pain; Enzyme inhibitors -- Periodicals; Enzyme Inhibitors -- periodicals; Biochemistry -- periodicals; 572.7
• DOI: 10.1080/14756366.2016.1260565
• Languages: English
• ISSNs: 1475-6366

Abstract

Abstract: Cannabinoid (CB) and opioid systems are both involved in analgesia, food intake, mood and behavior. Due to the co-localization of µ-opioid (MOR) and CB1 receptors in various regions of the central nervous system (CNS) and their ability to form heterodimers, bivalent ligands targeting to both these systems may be good candidates to investigate the existence of possible cross-talking or synergistic effects, also at sub-effective doses. In this work, we selected from a small series of new Rimonabant analogs one CB1R reverse agonist to be conjugated to the opioid fragment Tyr-D-Ala-Gly-Phe-NH2 . The bivalent compound (9 ) has been used for in vitro binding assays, for in vivo antinociception models and in vitro hypothalamic perfusion test, to evaluate the neurotransmitters release.